StockNews.com Initiates Coverage on Eiger BioPharmaceuticals (NASDAQ:EIGR)

StockNews.com assumed coverage on shares of Eiger BioPharmaceuticals (NASDAQ:EIGR) in a report published on Wednesday. The brokerage issued a sell rating on the biotechnology company’s stock.

Eiger BioPharmaceuticals Price Performance

Eiger BioPharmaceuticals has a 52 week low of $1.10 and a 52 week high of $43.35. The firm has a market cap of $2.55 million, a price-to-earnings ratio of -0.03 and a beta of 1.83. The company has a fifty day moving average price of $4.85 and a 200-day moving average price of $7.03.

About Eiger BioPharmaceuticals

Eiger BioPharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection.